LITIGATION RESULTING FROM NAS-NRC REVIEW AND FDA DEMANDS FOR NEW DRUG STATUS

被引：0
|
作者：
TEMKO, SL [1 ]
机构：
[1] COVINGTON & BURLING,WASHINGTON,DC
来源：
FOOD DRUG COSMETIC LAW JOURNAL | 1971年 / 26卷 / 10期
关键词：
D O I：
暂无
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：464 / 471
页数：8
相关论文
共 50 条
  • [41] A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007-2013
    Egger, Gunter F.
    Wharton, Gerold T.
    Malli, Suzanne
    Temeck, Jean
    Murphy, M. Dianne
    Tomasi, Paolo
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (05) : 639 - 647
  • [42] Sebotropic drug reaction resulting from kava-kava extract therapy: A new entity?
    Jappe, U
    Franke, I
    Reinhold, D
    Gollnick, HPM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (01) : 104 - 106
  • [43] From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt
    Elgarhy, Fadya M.
    Borham, Abdallah
    Alziny, Noha
    AbdElaal, Khlood R.
    Shuaib, Mahmoud
    Musaibah, Abobaker Salem
    Hussein, Mohamed Ali
    Abdelnaser, Anwar
    PHARMACEUTICALS, 2024, 17 (07)
  • [44] Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020
    Choi, Hyeyoung
    Lee, Hyesung
    Park, Bojung
    Kim, Chorong
    Lee, Jaehyun
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 552 - 560
  • [45] Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020
    Hyeyoung Choi
    Hyesung Lee
    Bojung Park
    Chorong Kim
    Jaehyun Lee
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 552 - 560
  • [46] Highly variable drugs: Observations from bioequivalence data submitted to the FDA for new generic drug applications
    Davit, Barbara M.
    Conner, Dale P.
    Fabian-Fritsch, Beth
    Haidar, Sam H.
    Jiang, Xiaojian
    Patel, Devvrat T.
    Seo, Paul R. H.
    Suh, Keri
    Thompson, Christina L.
    Yu, Lawrence X.
    AAPS JOURNAL, 2008, 10 (01): : 148 - 156
  • [47] Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications
    Barbara M. Davit
    Dale P. Conner
    Beth Fabian-Fritsch
    Sam H. Haidar
    Xiaojian Jiang
    Devvrat T. Patel
    Paul R. H. Seo
    Keri Suh
    Christina L. Thompson
    Lawrence X. Yu
    The AAPS Journal, 2008, 10 : 148 - 156
  • [48] The economic consequences of US FDA new drug approvals: evidence from Taiwan pharmaceutical and biotech companies
    Chen, Yong-Jie
    Feng, Zhi-Yuan
    Li, Yueh-Ping
    Huang, Hua-Wei
    INNOVATION-ORGANIZATION & MANAGEMENT, 2021, 23 (03): : 354 - 374
  • [49] FDA EXTENDS EDUCATIONAL PERIOD FOR NEW POLICY ON COMPOUNDING ANIMAL DRUGS FROM BULK DRUG SUBSTANCES
    不详
    JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2022, 260 (14): : 1772 - 1773
  • [50] Original Research: Intravenous Ribavirin-Review of the FDA's Emergency Investigational New Drug Database (1997-2008) and Literature Review
    Riner, Andrea
    Chan-Tack, Kirk M.
    Murray, Jeffrey S.
    POSTGRADUATE MEDICINE, 2009, 121 (03) : 139 - 146
12345